<DOC>
	<DOCNO>NCT01310777</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy Brinzolamide/Brimonidine lower intraocular pressure ( IOP ) relative individual active component patient open-angle glaucoma ocular hypertension .</brief_summary>
	<brief_title>Brinzolamide/Brimonidine Twice Day ( BID ) Fixed Combination ( FC ) v Brinzolamide BID Brimonidine BID Patients With Open Angle Glaucoma Ocular Hypertension</brief_title>
	<detailed_description>This study consist 7 visit conduct 2 sequential phase : screening/eligibility phase , include screen visit 2 eligibility visit , treatment phase , include 4 on-therapy visit conduct Week 2 , Week 6 , Month 3 , Month 6 ( early exit ) . Following washout IOP-lowering medication , subject meet inclusion/exclusion criterion eligibility visit IOP measurement within specified range period randomize 1 3 study drug group : Brinz/Brim , Brinz , Brim .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Brimonidine Tartrate</mesh_term>
	<mesh_term>Brinzolamide</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Diagnosed open angle glaucoma ocular hypertension , , opinion Investigator , insufficiently control monotherapy currently multiple IOPlowering medication . Meet qualify IOP entry criterion . Able understand sign inform consent form . Other protocolspecified inclusion criterion may apply . Women childbearing potential pregnant , test positive pregnancy Screening Visit , breastfeeding , agreement use adequate birth control method prevent pregnancy throughout study . Severe central visual field loss . Best correct visual acuity ( BCVA ) score bad 55 ETDRS letter ( 20/80 Snellen equivalent ) . Chronic , recurrent severe inflammatory eye disease . Ocular trauma within precede 6 month . Ocular infection ocular inflammation within precede 3 month . Clinically significant progressive retinal disease . Other ocular pathology . Intraocular surgery within 6 month prior entry . Ocular laser surgery within 3 month prior entry . Any abnormality prevent reliable applanation tonometry . Any condition , include severe illness , would make subject , opinion Investigator , unsuitable study . Recent use highdose ( &gt; 1 gram daily ) salicylate therapy . Recent , current , anticipated treatment medication augments adrenergic response , precludes use alphaadrenergic agonist . Concurrent use glucocorticoid medication administer route . Other protocolspecified exclusion crtieria may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Open-Angle glaucoma</keyword>
	<keyword>Ocular Hypertension</keyword>
	<keyword>OAG</keyword>
	<keyword>OHT</keyword>
</DOC>